MAPT and Alzheimer disease: To date, as florbetapir 18F amyloid PET and CSF Aβ1-42 are reported to reflect the brain amyloid burden with high specificity36, 37, multiple neuroimaging measures, along with CSF proteins (Aβ1-42 and tau) could be proposed as critical markers in biological research and clinical trials in AD pathophysiological process38.